Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 8/20 | 0.55 |
| ▸ | BUB1 | O43683 | 7/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etriciguat SCHEMBL29388720 | 1.00 | ADORA3 (0.56) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL18212218 | 0.94 | ADORA3 (0.58) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6068522 | 0.93 | ADORA3 (0.49) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL25688767 | 0.89 | PDE5A (0.57) | ADORA3KCNH2PDE5ABUB1 | |
| SCHEMBL6068302 | 0.89 | BUB1 (0.47) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL6217157 | 0.87 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6068406 | 0.87 | BUB1 (0.48) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL6068827 | 0.86 | L3MBTL1 (0.47) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL174189 | 0.86 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL16594600 | 0.86 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498298-A1 | THE USE OF SGC STIMULATORS AND SGC ACTIVATORS ALONE OR IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOGENESIS IMPERFECTA (OI) | Bayer AG (DE) | 2019-06-19 | — | — | EP | claimed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | claimed |
| EP-3291811-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177660-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | claimed |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELl SCHAFT (DE) | 2016-06-09 | — | — | US | claimed |
| EP-2531187-B1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | ADVERIO PHARMA GMBH (DE) | 2015-08-12 | — | — | EP | claimed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | claimed |
| EP-2531187-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | Bayer Intellectual Property GmbH (DE) | 2012-12-12 | — | — | EP | claimed |
| US-20120022028-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | claimed |
| EP-2387404-A2 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Bayer Pharma Aktiengesellschaft (DE) | 2011-11-23 | — | — | EP | claimed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | claimed |
| US-20110092500-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-21 | — | — | US | claimed |
| EP-2296661-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-23 | — | — | EP | claimed |
| US-20100210643-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | US | claimed |
| WO-2010081647-A2 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | WO | claimed |
| EP-2144605-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | Bayer HealthCare AG (DE) | 2010-01-20 | — | — | EP | claimed |
| WO-2009138165-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | claimed |
| WO-2008138483-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | claimed |
| EP-1499369-A1 | STENTS CONTAINING PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003089024-A1 | STENTS CONTAINING PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-10-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE5A, PDE3B, PDE3A | ADORA3 1626/4885KCNH2 1362/4885PDE5A 1/4885 |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | ADORA3 3072/4885KCNH2 2945/4885PDE5A 1/4885 |
| US-20110092500-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | GUCY1A2, GUCY1A1, GUCY1B1 | ADORA3 301/4885KCNH2 897/4885PDE5A 10/4885 |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | PDE5A, PDE3A, GMPS | ADORA3 1527/4885KCNH2 1661/4885PDE5A 1/4885 |
| US-20100210643-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | PDE5A, PDE3B, PDE3A | ADORA3 2112/4885KCNH2 2632/4885PDE5A 1/4885 |
| US-20120022028-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PDE5A, PDE3A, PDE3B | ADORA3 1516/4885KCNH2 2274/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.